VAXCYTE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 116.00 USD | +1.64% |
|
+3.96% | +84.71% |
| 10/09 | Analyst recommendations: Apple, Oracle, Progressive, Dollar Tree... |  |
| 10/09 | Mizuho Boosts Price Target on Vaxcyte to $163 From $113, Maintains Outperform Rating | MT |
Sales 2023 by Business Segment
Sales 2023 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
Biological Products | |||||||
Total Assets | 6.57Cr | 39Cr | 32Cr | 100.62Cr | 140.79Cr | ||
Interest Expense | -40T | -7T | -7T | -2T | - | ||
CAPEX | -11.95L | -11.55L | -65.55L | -58.48L | -6.79Cr | ||
EBT | -5.03Cr | -8.92Cr | -10Cr | -22Cr | -40Cr | ||
D&A | 12.32L | 14.05L | 34.57L | 91.96L | 1.02Cr | ||
Operating Income | -5.42Cr | -8.96Cr | -10Cr | -23Cr | -47Cr | ||
Net Income | -5.03Cr | -8.92Cr | -10Cr | -22Cr | -40Cr |
Geographical Revenue Distribution History
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
Total Assets | 6.57Cr | 39Cr | 32Cr | 100.62Cr | 140.79Cr | ||
Interest Expense | - | -7T | -7T | -2T | - | ||
D&A | - | 14.05L | 34.57L | 91.96L | 1.02Cr | ||
CAPEX | - | -11.55L | -65.55L | -58.48L | -6.79Cr | ||
Net Income | - | -8.92Cr | -10Cr | -22Cr | -40Cr | ||
EBT | - | -8.92Cr | -10Cr | -22Cr | -40Cr | ||
Operating Income | - | -8.96Cr | -10Cr | -23Cr | -47Cr |
- Stock Market
- Equities
- PCVX Stock
- Financials Vaxcyte, Inc.
- Business Segments
MarketScreener is also available in this country: United States.
Switch edition